Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2375467 | 0.98 | HPGD (0.51) | KMT2AMEN1HPGDHSD17B10CTSC | |
| SCHEMBL10722024 | 0.98 | HPGD (0.51) | KMT2AMEN1HPGDHSD17B10CTSC | |
| SCHEMBL1930288 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL4916614 | 0.89 | HSD17B10 (0.47) | KMT2AMEN1HPGDHSD17B10HRH3 | |
| Acetic Acid SCHEMBL9372583 | 0.87 | HPGD (0.53) | KMT2AMEN1HPGDCTSCPOLB | |
| SCHEMBL8643295 | 0.82 | HSD17B10 (0.41) | KMT2AMEN1HPGDHSD17B10HRH3 | |
| SCHEMBL2679157 | 0.82 | GBA1 (0.52) | KMT2AHSD17B10HRH3POLBMAPT | |
| SCHEMBL13681486 | 0.82 | HSD17B10 (0.46) | KMT2AMEN1HPGDHSD17B10HRH3 | |
| SCHEMBL29064506 | 0.81 | HRH3 (0.42) | KMT2AMEN1HPGDHSD17B10HRH3 | |
| SCHEMBL8110624 | 0.79 | HRH3 (0.51) | KMT2AMEN1HSD17B10HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3036221-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | Luc Therapeutics, Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-0690863-B1 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LAB (US) | 2003-03-05 | — | — | EP | disclosed |
| CN-1046723-C | Tetracyclic compounds as dopamine agonists | ABBOTT LAB (US) | 1999-11-24 | — | — | CN | disclosed |
| US-5597832-A | TREATMENT OF NEUROLOGICAL, PSYCHOLOGICAL, CARDIOVASCULAR DISORDERS, AND SUBSTANCE ABUSE, BEHAVIOR DISORDERS, COGNITIVE IMPAIRMENT AND ATTENTION DEFICIT DISORDER | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| CN-1124489-A | Tetracyclic compounds as dopamine agonists | ABBOTT LAB (US) | 1996-06-12 | — | — | CN | disclosed |
| EP-0690863-A1 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0690863-A4 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LAB (US) | 1995-11-07 | — | — | EP | disclosed |
| WO-1994022858-A1 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1994-10-13 | — | — | WO | disclosed |
| US-4647585-A | Bicycloheptane substituted ethers | E. R. SQUIBB & SONS, INC. (US) | 1987-03-03 | — | — | US | disclosed |
| US-4608386-A | ASTHMA | E. R. SQUIBB & SONS, INC. (US) | 1986-08-26 | — | — | US | disclosed |
| US-4258198-A | ANTHELMINTICS | SMITHKLINE CORPORATION (US) | 1981-03-24 | — | — | US | disclosed |
| US-4025638-A | ANTHELMINTICS | SMITHKLINE CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | KMT2A 4060/4885MEN1 3855/4885HPGD 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.